MaxCyte, Inc. (NASDAQ:MXCT) Given Consensus Rating of “Hold” by Brokerages

MaxCyte, Inc. (NASDAQ:MXCT) has received an average rating of “Hold” from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $5.50.

Several equities analysts have commented on the company. Weiss Ratings upgraded MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Craig Hallum decreased their price objective on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, March 25th.

Institutional Investors Weigh In On MaxCyte

Hedge funds and other institutional investors have recently made changes to their positions in the business. Capricorn Fund Managers Ltd bought a new position in shares of MaxCyte in the first quarter worth about $5,760,000. Mirabella Financial Services LLP boosted its stake in MaxCyte by 24.2% during the 3rd quarter. Mirabella Financial Services LLP now owns 8,200,000 shares of the company’s stock valued at $12,956,000 after purchasing an additional 1,600,000 shares during the period. State Street Corp grew its holdings in MaxCyte by 4.0% in the 4th quarter. State Street Corp now owns 2,358,384 shares of the company’s stock valued at $3,655,000 after buying an additional 91,534 shares during the last quarter. AXA S.A. increased its position in MaxCyte by 123.2% in the 2nd quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock worth $4,801,000 after buying an additional 1,215,481 shares during the period. Finally, Brooklands Fund Management Ltd bought a new position in MaxCyte in the 1st quarter worth approximately $1,538,000. 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Price Performance

Shares of NASDAQ:MXCT opened at $1.22 on Friday. The stock has a market capitalization of $130.15 million, a P/E ratio of -3.28 and a beta of 1.47. The business has a 50-day moving average of $1.08 and a two-hundred day moving average of $1.03. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $2.37.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.06. MaxCyte had a negative return on equity of 20.03% and a negative net margin of 121.16%.The business had revenue of $6.22 million for the quarter, compared to analyst estimates of $7.28 million. As a group, research analysts expect that MaxCyte will post -0.29 EPS for the current fiscal year.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical?stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical?scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.